Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2012
  • Online publication date: August 2012

Chapter 11 - Testosterone, obesity, diabetes and the metabolic syndrome

11.13 References

AlbertiKGMM, EckelRH, GrundySM, ZimmetPZ, CleemanJI, DonatoKA, FruchartJ-C, JamesWPT, LoriaCM, SmithSC (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645
AllanCA, McLachlanRI (2010) Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17:224–232
AnderssonB, MarinP, LissnerL, VermeulenA, BjorntorpP (1994) Testosterone concentrations in women and men with NIDDM. Diabetes Care 17:405–411
BirkelandKI, HanssenKF, TorjesenPA, VaalerS (1993) Level of sex hormone binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin End Metab 76:275–278
BjorntorpP (1996) The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 20:291–302
Blouin, K, DespresJP, CouillardC, TremblayA, Prud'hommeD, BouchardC, TchernufA (2005) Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54:1034–1040
BlouinK, BoivinA, TchernofA (2008) Androgens and body fat distribution. J Steroid Biochem Mol Biol 108:272–280
BocchiEA, CarvalhoVO, GuimaraesGV (2008) Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Int Braz J Urol 34:302–310
BojesenA, JuulS, GravholtCH (2003) Prenatal and postnatal prevalence of Klinefelter's syndrome: a national registry study. J Clin Endocrinol Metab 88:622–628
BojesenA, KristensenK, BirkebackNH (2006) The metabolic syndrome is frequent in men with Klinefelter's Syndrome. Diabetes Care 29:1591–1598
BonoraE, FormentiniG, CalcaterraF, LombardiS, MariniF, ZenariL, SaggianiF, PoliM, PerbelliniS, RaffaelliA, CacciatoriV, SantiL, TargherG, BonadonnaR, MuggeoM (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135–1141
CohenP (1999) The hypogonadal-obesity-cycle. Med Hypothesis 52:49–51
CoronaG, MannucciE, SchulmanC, PetroneL, MansaniR, CilottiA, BalerciaG, ChiariniV, FortiG, MaggiM (2006) Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 50:595–604
CorralesJJ, AlmeidaM, BurgoR, MoriesMT, MirallesJM, OrfaoA (2006) Androgen replacement therapy depresses the ex-vivo production on inflammatory cytokines by circulating antigen-presenting cells in aging type 2 diabetic men with partial androgen deficiency. J Endocrinol 189:595–604
CouillardC, GagnonJ, BergeronJ, LeonAS, RaoDC, SkinnerJS, WilmoreJH, DesprésJP, BouchardC (2000) Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concemtrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 85:1026–1031
De PergolaG (2000) The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 24 (Suppl 2):S59–S63
DhindsaS, PrabhakarS, SethiM, Bandyo PadhyayA, ChaudhuriA, DandonaP (2004) Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462–5468
DingEL, SongY, MansonJE, HunterDJ, LeeCC, RifaiN, BuringJE, GazianoJM, LiuS (2009) Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361:1152–1163
DockeryF, BulpittCJ, AgarwalS, DonaldsonM, RajkumarC (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 104:195–201
EndreT, MattiassonI, BerglundG, HulthenUL (1996) Low testosterone and insulin resistance in hypertension prone men. J Hum Hypertens 10:755–761
FarisJE, SmithMR (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17:240–246
GeorgeJT, MillerRP, AndersonRA (2010) Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 91:302–307
GrundySM, BrewerHB Jr, CleemanJI, SmithSC Jr, LenfantC (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438
GuayAM, BansalS, HeatleyGJ (1995) Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 80:3546–3552
HaffnerSM, ValdezRA, SternMP, KatzMS (1993) Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 17:643–649
HaffnerSM, ShatenJ, SternMP, SmithGD, KullerL (1996) Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol 143:889–897
HaiderA, YassinA, SaadF, ShabsighR (2007) Effect of androgen deprivation on glycaemic control and on cardiovascular risk factors in men with advanced prostate cancer with diabetes. Aging Male 10:189–196
HaringR, VolzkeH, FelixSB, SchipfS, DorrM, RosskopfD, NauckM, SchoflC, WallaschofskiH (2009) Prediction of metabolic syndrome by low serum testosterone levels in men. Results from the study of health in Pomerania. Diabetes Care 58:2027–2031
HeufelderAE, SaadF, BunckMC, GoorenL (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726–733
IsidoriAM, CaprioM, StrollF, MorettiC, FrajeseG, IsidoriA, FabbriA (1999) Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levelsJ Clin Endocrinol Metab 84:3673–3680
IsidoriAM, GiannettaE, GianfrilliD, GrecoEA, BonifacioV, AversaA, IsidoriA, FabbriA, LenziA (2005a) Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 63:381–394
IsidoriAM, GianettaE, GrecoEA, GianfrilliD, BonifacioV, IsidoriA, LenziA, FabbriA (2005b) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280–293
JonesTH (2007) Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. Eur Urol Suppl 6:847–857
JonesTH (2010) Testosterone deficiency: a risk factor for cardiovascular disease?Trends Endocrinol Metab 21:496–503
JonesTH, KennedyRL (1993) Cytokines and hypothalamic-pituitary function. Cytokine 5:531–538
JonesTH, SaadF (2009) The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207:318–327
JonesTH, ArverS, BehreHM, BuvatJ, MeulemanE, MoncadaI, MoralesAM, VolterraniM, YellowleesA, HowellJD, ChannerKS (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (The TIMES2 Study). Diabetes Care 34:828–837
KalinchenkoSY, TishovaYA, MskhalayaGJ, GoorenLJ, GiltayEJ, SaadF (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 73:602–612
KangHY, ChoCL, HuangKL, WangJC, HuYC, LinHK, ChangC, HuangKE (2004) Nongenomic androgen activation of phosphatidylinositol3-kinase/Akt signalling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res 19:1181–1190
KapoorD, MalkinCJ, ChannerKS, JonesTH (2005) Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 63:239–250
KapoorD, GoodwinE, ChannerKS, JonesTH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899–906
KapoorD, AldredH, ClarkS, ChannerKS, JonesTH (2007a) Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911–917
KapoorD, ClarkeS, ChannerKS, JonesTH (2007b) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156:595–602
KapoorD, ClarkeS, ChannerKS, JonesTH (2007c) Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 30:500–507
KeatingNL, O'MalleyAJ, FreedlandSJ, SmithMR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39–46
KhawKT, Barrett-ConnorE (1988) Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 6:329–332
KhawKT, Barrett-ConnorE (1992) Lower endogenous androgens predict central adiposity in men. Am Epidemiol 2:675–682
KupelianV, PageST, AraujoAB, TravisonTG, BremnerWJ, McKinlayJB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 91:843–850
LaaksonenDE, NiskanenL, PunnonenK, NyyssonenK, TuomainenTP, ValkonenVP, SalonenR, SalonenJT (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041
LaaksonenDE, NiskanenL, PunnonenK, NyyssonenK, TuomainenTP, ValkonenVP, SalonenJT (2005) The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712–719
LapauwB, OuwensM, HartLM, WuytsB, HolstJJ, T'SjoenG, KaufmanJM, RuigeJB (2010) Sex steroids affect triglyceride handling, glucose-dependent insulinotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men. Diabetes Care 33:1831–1833
LevineGN, D'AmicoAV, BergerP, ClarkPE, EckelRH, KeatingNL, MilaniRV, SagalowskyAI, SmithMR, ZakaiN (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833–840
LovesS, Ruinemans-KoertsJ, de BoerH (2008) Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 158:741–747
MacDonaldAA, HerbisonGP, ShowellM, FarquharCM (2010) The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update 16:293–311
MaggioM, LauretaniF, CedaGP, BandinelliS, BasariaS, BleA, EganJ, PaolissoG, NajjarS, Jeffrey MetterE, ValentiG, GuralnikJM, FerrucciL (2006) Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc 54:1832–1838
MalkinCJ, PughPJ, JonesRD, KapoorD, ChannerKS, JonesTH (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89:3313–3318
MarinP, KrotkiewskiM, BjorntorpP (1992a) Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1:329–336
MarinP, HolmangS, JonssonL, SjostromL, KvistH, HolmG, LindstedtG, BjorntorpP (1992b) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997
MarinP, HolmangS, GustafssonC, JonssonL, KvistH, ElanderA, EldhJ, SjostromL, HolmG, BjorntorpP (1993) Androgen treatment of abdominally obese men. Obes Res 1:245–251
MullerM, GrobbeeDE, den TonkelaarI, LambertsSW, van der SchouwYT (2005) Endogenous sex hormones and metabolic syndrome in aging men. Clin Endocrinol Metab. 90:2618–2623
NettleshipJE, JonesTH, ChannerKS, JonesRD (2007) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect independent of the classic androgen receptor. Circulation 116:2427–2434
OhJY, Barrett-ConnorE, WedickNM, WingardDL (2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women. Diabetes Care 25:55–60
PasqualiR, CasimirriF, CantobelliS, MelchiondaN, Morselli LabateAM, FabbriR, CapelliM, BortoluzziL (1991) Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 40:101–104
PitteloudN, HardinM, DwyerAA, ValassiE, YialamasM, ElahiD, HayesFJ (2005a) Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636–2641
PitteloudN, MoothaVK, DwyerAA, HardinM, LeeH, ErikssonKF, TripathyD, YialamasM, GroopL, ElahiD, HayesFJ (2005b) Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28:1636–1642
SatoK, IemitsuM, AizawaK, AjisakaR (2008) Testosterone and DHEA activate the glucose metabolism-related signalling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 294:E961–E968
SeidellJC, BjorntorpP, SjostromL, KvistH, SannerstedtR (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897–901
SelvinE, FeinleibM, ZhangL, RohrmannS, RifaiN, NelsonWG, DobsA, BasariaS, GoldenSH, PlatzEA (2007) Androgens and diabetes in men. Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30:234–238
SimonD, PreziosiP, Barrett-ConnorE, RogerM, SaintpaulM, NahoulK, PapozL (1992) Interrelation between plasma testosterone and plasma-insulin in healthy adult men – the Telecom study. Diabetologia 35:173–177
SimonD, CharlesMA, NahoulK, OrssaudG, KremskiJ, HullyV, JoubertE, PapozL, EschwegeE (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 82:682–685
SinghR, ArtazaJN, TaylorWE, Gonzalez-CadavidNF, BhasinS (2003) Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144:5081–5088
SmithJC, BennettS, EvansLM, KynastonHG, ParmarM, MasonMD, CockcroftJR, ScanlonMF, DaviesJS (2001) The effects of induced hypogonadism on arterial stiffness, body composition and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267
SmithMR, FinkelsteinJS, McGovernFJ, ZietmanAL, FallonMA, ShoenfeldDA, KantoffPW (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603
SmithMR, LeeH, NathanDM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305–1308
StanworthRD, KapoorD, ChannerKS, JonesTH (2008) Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol 159:736–746
StanworthRD, KapoorD, ChannerKS, JonesTH (2009) Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 32:541–546
StanworthRD, KapoorD, ChannerKS, JonesTH (2011) Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clin Endocrinol (Oxf) 74:624–630
StellatoRK, FeldmanHA, HamdyO, HortonES, McKinlayJB (2000) Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men. Diabetes Care 23:490–494
StrainGW, ZumoffB, MillerL, RosnerW, LevitC, KalinM, HershcopfRJ, RosenfeldRS (1988) Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 66:1019–1023
StratonIM, AdlerAI, NeilAW, MatthewsDR, ManleySE, CullCA, HaddenD, TurnerRC, HolmanRR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
SvartbergJ, von MuhlenD, SundsfjordJ, JordeR (2004a) Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 19:657–663
SvartbergJ, von MuhlenD, SchirmerH, Barrett-ConnorE, SundsfjordJ, JordeR (2004b) Association of endogenous testosterone with blood pressure and left ventricular mass in men: the Tromso study. Eur J Endocrinol 159:65–71
TibblinG, AdlerberthA, LindstedtG, BjorntorpP (1996) The pituitary–gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 45:1605–1609
TsaiEC, BoykoEJ, LeonettiDL, FujimotoWY (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24:485–491
Van PottelberghI, BraeckmanL, De BacquerD, De BackerG, KaufmanJM (2003) Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166:95–102
WangC, SwerdloffRS, IranmaneshA, DobsA, SnyderPJ, CunninghamG, MatsumotoAM, WeberT, BermanN; Testosterone Gel Study Group (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85:2839–2853
WangC, NieschlagE, SwerdloffR, BehreHM, HellstromWJ, GoorenLJ, KaufmanJM, LegrosJJ, LunenfeldB, MoralesA, MorleyJE, SchulmanC, ThompsonIM, WeidnerW, WuFCW (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159:507–514
WangC, JacksonG, JonesTH, MatsumotoAM, NehraA, PerelmanMA, SwerdloffRS, TraishA, ZitzmannM, CunninghamG (2011) Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34:1669–1675
XuT, WangX, HouS, ZhuJ, ZhangX, HuangX (2002) Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin Med J 115:1336–1340
YialamasMA, DwyerAA, HanleyE, LeeH, PitteloudN, HayesFJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 92:4254–4259
ZimmetP, MaglianoD, MatsuzawaY, AlbertiG, ShawJ (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295–300
ZitzmannM (2009) The role of CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 37:52–61
ZmudaJM, ThompsonPD, DickensonR, BaussermannLL (1996) Testosterone decreases lipoprotein(a) in men. Am J Cardiol 77:1244–1247
ZumoffB, MillerLK, StrainGW (2003) Reversal of the hypogonadotropic hypogonadism of obese men by the administration of the aromatase inhibitor testolactone. Metabolism 52:1126–1128